News & Updates
Filter by Specialty:
Starting vedolizumab early better than late for UC
Starting vedolizumab early after the diagnosis of ulcerative colitis (UC) appeared more effective than delaying it to after initiation of other UC treatments, according to the RALEE study.
Starting vedolizumab early better than late for UC
21 Feb 2022
Being physically active helps prevent NAFLD
Physical activity (PA) is associated with a lower prevalence of nonalcoholic fatty liver disease (NAFLD), with greater benefits for higher PA intensities, reveals a study. Better metabolic health, particularly lower waist circumference and insulin resistance, mediates this association.
Being physically active helps prevent NAFLD
18 Feb 2022
Trastuzumab biosimilar on par with reference agent in HER2-positive gastric cancer
CT-P6, a trastuzumab biosimilar approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (AGC), is as efficacious as reference trastuzumab in terms of response rates, progression-free (PFS) and overall survival (OS), a study has shown.
Trastuzumab biosimilar on par with reference agent in HER2-positive gastric cancer
16 Feb 2022
COVID-19 infection relatively rare in vaccinated IBD patients
Patients with inflammatory bowel disease (IBD) who have completed a COVID-19 vaccine regimen have a low risk of developing COVID-19, though receipt of mRNA vaccines may offer better protection, according to a small study presented at the Crohn’s and Colitis Congress 2022.
COVID-19 infection relatively rare in vaccinated IBD patients
15 Feb 2022
Long-term PEN therapy promising in children with mild Crohn’s disease
Partial enteral nutritional (PEN) therapy shows potential in the long-term management of mild paediatric Crohn’s disease, helping to avoid the use of corticosteroids and prevent side effects commonly observed with other inflammatory bowel disease therapies, according to a study presented at the virtual Crohn's & Colitis Congress.